Objective:

To discuss the implications of adopting anticomplement therapy for geographic atrophy (GA) in clinical practice, focusing on candidate selection and practice management.

Key Findings:

• Anticomplement therapy provides a new treatment option for GA, a previously untreatable condition.
• Patient selection is influenced by the status of the fellow eye, with those with vision loss in one eye more likely to pursue treatment.
• Increased patient volume due to GA therapy may strain practice resources and require adjustments in management.

Interpretation:

The introduction of anticomplement therapy for GA presents both opportunities and challenges in clinical practice, necessitating careful consideration of patient selection and resource management.

Limitations:

• The lenient drug labels may lead to over-treatment of asymptomatic patients.
• Increased patient volume may overwhelm practices not equipped to handle chronic therapy management.

Conclusion:

While anticomplement therapy for GA is a significant advancement, it requires thoughtful implementation in clinical settings to ensure effective patient care.